Markets
E.l.f. beauty shares rip after it receives market upgrade
(Michael M. Santiago/Getty Images)

e.l.f Beauty rips after Morgan Stanley upgrade

The market is too worried about the cosmetic company’s price hikes, the analysts say.

Matt Phillips

Cosmetics company e.l.f. Beauty jumped Monday after Morgan Stanley upgraded its rating on the stock to “over-weight” from “equal-weight” and raised its price target to $134 from $114.

Despite reporting results that more or less beat Wall Street expectations last week, e.l.f. saw its share price plunge as executives sounded less than certain that consumers would swallow the large price hikes the company is putting in place this month to offset tariff-related costs.

“With these increases just going in on August 1, we’re still reading how the consumer will respond to that,” e.l.f. CEO Mandy Fields told analysts. “It will take a couple of weeks for that to fully roll out within retail. And so that is something that we’re watching for.”

e.l.f. shares fell 9.5% the next day. But with a few days of perspective, Morgan Stanley analysts led by Dara Mohsenian have decided the market, basically, got it wrong. In a note published Monday, they wrote:

“We Believe Bear Concerns on Pricing Demand Elasticity Risk Are Overblown: ELF implemented a 14% weighted price increase on August 1... Bear worries on pricing stem from a few areas: a) low income consumers are under severe pressure in the US to begin with, so any ELF price increases could drive a large demand reaction, b) ELF has never taken such a large magnitude of price increases across its portfolio, and c) ELF has never taken pricing across its entire portfolio at once. Thus, we believe the market/consensus is currently assuming a sizeable demand elasticity response to ELF’s price increase.”

Morgan Stanley argues that’s wrong for a few reasons. One, they said, is that consumers tend to be not especially sensitive to the pricing of beauty products they use, “given the relative importance of beauty products to consumers.”

They added that e.l.f. cosmetics are already pretty cheap compared to other options, meaning there’s less opportunity for consumers to find more affordable substitutes.

The analysts also looked to the experience of consumer packaged goods companies during the 2022 inflationary period, when many companies pushed substantial price increases. The takeaway from that experience, the analysts wrote, is that sales volumes tended to react more or less similarly to small or large price increases.

In other words, while companies did lose some sales because of big price increases, sales didn’t decline anywhere near as much as prices increased. Thus companies were able to recoup any lost sales by charging more. And that’s a big part of the reason why US corporate profit surged at the time.

More Markets

See all Markets
markets

Intel sinks on news it will hang on to networking unit

Intel dropped in early trading Thursday after it disclosed plans to retain ownership of its networking unit following a strategic review of operations.

The unit, known as NEX, makes products like infrastructure processors, which do needed “housekeeping” tasks like running security checks, thereby freeing core Intel CPUs to do the higher-value operations. It also produces switches and controllers that manage and direct the flow of data to CPUs.

markets

Quantum computing stocks soar on return of bullish options bets

The calendar says December, but the price action is starting to look a lot more like September to me:

Quantum computing companies IonQ, Rigetti Computing, and D-Wave Quantum are all up at least 7% as of 11:04 a.m. ET, buoyed by a wave of bullish options activity.

  • Nearly 50,000 calls in IonQ have already changed hands, well above the 20-day average for a full session, with activity concentrated in strikes from $50 to $55 in contracts that expire between Friday and mid-January. Its put/call ratio is near 0.2, versus an average of over 1 for the past 20 sessions.

  • More than 65,000 calls have traded in Rigetti, a hair shy of its full 20-day average. Like IonQ, options activity has a bullish tilt, with a put/call ratio of about 0.7 versus a 20-day average of roughly 1.2.

  • D-Wave, which received positive commentary from Evercore ISI on Wednesday, isn’t seeing call activity as elevated as its peers, but the options action is also very skewed toward the bull side, with a put/call ratio of less than 0.3 versus a 20-session average of 0.7.

Pure-play quantum computing stocks nearly doubled from late August to late September amid heavy options market activity thanks to reports on government support for the sector, M&A activity, tech breakthroughs, and a flurry of price target hikes by Wall Street.

markets

Hims announces acquisition of Canadian telehealth firm Livewell

Hims & Hers rose in early trading after it announced its acquisition of Livewell, a Canadian telehealth company, marking its official entrance to that market.

The company announced in July that it would expand into Canada by 2026, taking advantage of the patent expiry for semaglutide, the active ingredient in Novo Nordisk’s blockbuster GLP-1s, Ozempic and Wegovy. Hims said Thursday that it would do that through an all-cash acquisition of Livewell.

Novo’s patent on semaglutide is set to expire in Canada in January. It would be the first time generics for the blockbuster GLP-1 drugs are available anywhere, and generic drugmaker Sandoz International has already announced plans to make copies of the drug. In the US, Hims sells copycat versions of Novo’s drugs, which has led to conflict between the companies.

On Wednesday, Hims announced that it would purchase YourBio, a device that uses “bladeless microneedles thinner than an eyelash” to collect blood samples, in another all-cash deal. According to its latest quarterly filing, the company had $345.8 million in cash and cash equivalents.

markets

Symbiotic tanks as company and SoftBank, its largest shareholder, announce offering of 10 million shares

Symbiotic was among the robotics companies that popped on Wednesday, gaining nearly 10% on the news that the Trump administration was on the precipice of a major push to support the industry.

So naturally, management thinks its a good time to sell shares — and its largest shareholder, SoftBank, agrees.

After the close on Wednesday, management announced an offering of 10 million shares, with 6.5 million of that as a primary offering from the company to raise money for general corporate purposes, and 3.5 million from a secondary sale by SoftBank, which owns over one-third of its shares.

The stock cratered on the announcement, giving back all of its one-day gains and then some.

Symbiotic went public in 2022 through a SPAC merger with a SoftBank-backed affiliate.

In October, SoftBank sold its entire $5.8 billion stake in Nvidia to meet an upcoming payment to OpenAI to finance its equity position in the company. Since SoftBank is slated to pay the ChatGPT maker more than $20 billion this month, it would appear that this is another step toward raising the needed cash for that position.

We’ll see if this divestment makes SoftBank founder Masayoshi Son cry.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.